Nexus Dynamix
Bringing space to Earth: AI-powered microgravity for drug discovery, oncology, and regenerative medicine.
| EUR | 2025 |
|---|---|
| EBITDA | 0000 |
| % EBITDA margin | (300 %) |
| Profit | 0000 |
| % profit margin | (367 %) |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
| R&D % of revenue | 400 % |
Related Content
AstroPod is a next-generation biotech platform that brings space to Earth. Using a precision-engineered, 3-axis system, AstroPod simulates microgravity conditions on the ground — enabling faster and more stable drug crystallization, tissue engineering, and regenerative medicine workflows.
What sets AstroPod apart is its integrated AI agent, trained on over 750 crystallization experiments from NASA and ESA. This allows researchers to identify optimal crystal growth conditions with higher accuracy and in less time, dramatically reducing failure rates in early-stage drug development.
With a TRL-7 prototype validated and €1.2M raised, AstroPod supports biotech and pharma companies, CROs, and academic labs with a scalable, AI-guided alternative to costly and delayed space-based testing.